Hydrocephalus is a medical condition that affects the brain and occurs when there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. This condition can cause an increase in pressure within the brain, leading to symptoms such as headache, nausea, vomiting, and cognitive impairment. Hydrocephalus can be congenital, acquired, or idiopathic, and it is estimated to affect approximately 1 in every 500 births.

The global hydrocephalus market is expected to grow significantly in the coming years due to the increasing prevalence of the condition, rising healthcare expenditure, and advancements in medical technology. According to a report by Stratview Research, the hydrocephalus market was estimated at US$ 7.1 billion in 2021 and is expected to grow at a CAGR of 4.35% during 2022-2028 to reach US$ ~8.56 billion in 2028.

One of the key drivers of the hydrocephalus market is the growing prevalence of the condition, especially among the elderly population. As the global population continues to age, the incidence of hydrocephalus is expected to rise, creating a growing demand for treatment options. Additionally, the increasing awareness about the condition and its symptoms among healthcare professionals and patients is expected to drive the growth of the market.

The market is divided based on type, diagnostic & treatment, age group, and end user. On the basis of type, the market is further segmented into congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus and ex-vacuo hydrocephalus. In 2021, the congenital segment accounted for the biggest market share; throughout the forecast period, the segment is anticipated to see the highest CAGR.

On the basis of diagnostic & treatment, the market is divided into diagnostic and treatment.

On the basis of age group, the market is segmented into pediatric and adult. Pediatrics had a greater market share in 2021, and it is anticipated that it would grow at a faster rate over the course of the projection period.

On the basis of end user, the market is divided into hospitals, clinics, diagnostic centers and academic institutions and research organizations. In 2021, the hospital sector had the biggest market share, and throughout the forecast period, it is anticipated to grow at the highest CAGR.

The hydrocephalus market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America dominated the market for hydrocephalus shunts in 2021. 

Request a sample here:

https://www.stratviewresearch.com/Request-Sample/3162/hydrocephalus-market.html#form

Due to its stronger healthcare infrastructure, which encourages the use of technologically advanced shunts, and its rising hydrocephalus awareness, the US is a significant contributor to the market in this area. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that 1-2 out of every 1,000 children born in the US will have hydrocephalus. According to the University of California's Los Angeles Health Organization, 125,000 Americans currently have cerebrospinal fluid shunts in place.

The overall competitive landscape has been affected due to these mergers and acquisitions. The following are the major players in the hydrocephalus market:

  • Bicakcilar
  • Anuncia Inc.
  • B. Braun Melsungen AG
  • CHRISTOPH MIETHKE GMBH & CO. KG
  • Desu Medical
  • G. SURGIWEAR LTD
  • Integra LifeSciences
  • KANEKA MEDIX CORP
  • KARL STORZ SE & Co. KG
  • Medtronic
  • Möller Medical GmbH
  • Natus Medical Incorporated
  • Próteses, inc.
  • Sophysa 
  • Spiegelberg GmbH & Co.KG

In conclusion, the global hydrocephalus market is expected to grow significantly in the coming years, owing to the increasing prevalence of the condition, rising healthcare expenditure, and advancements in medical technology. The market is expected to be driven by the growing demand for treatment options among the elderly population, increasing awareness about the condition among healthcare professionals and patients, and the availability of advanced medical equipment and infrastructure.